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ABSTRACT
Background: An increasing number of elderly patients
diagnosed with achalasia are being referred for minimally
invasive myotomy. Little data are available about the op-
erative outcomes in this population. The objective of this
study was to review our experience with this procedure in
an elderly population.
Methods: A retrospective review was performed of 51
consecutive patients, 65 years of age or older, diagnosed
with achalasia who underwent a minimally invasive my-
otomy at our institution. Prior therapies, perioperative
outcomes, and postoperative interventions were also an-
alyzed.
Results: Of the 51 patients, 28 (55%) had undergone prior
endoscopic therapy, and 2 patients (7%) had a prior my-
otomy. Mean duration of symptoms was 10.9 years (range,
0.5 to 50). No perioperative mortality occurred, and the
median hospital stay was 3 days. Two patients (3.8%) had
complications, including a gastric mucosal injury and one
atelectasia. Eleven patients (21%) required additional ther-
apy postoperatively. Symptom improvement was de-
scribed in all patients.
Conclusion: Laparoscopic Heller myotomy can safely be
performed in elderly patients, providing significant symp-
tom relief. No evidence suggests that surgery should not
be considered a first-line treatment. Advanced age does
not appear to adversely affect outcomes of laparoscopic
Heller myotomy.
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INTRODUCTION
Although achalasia is the most common functional disor-
der of the esophageal body and lower esophageal sphinc-
ter (LES), it occurs rarely, with a prevalence of 1/10 000
and an incidence between 0.03 and 1/100 000 per year.1–7
Achalasia affects both sexes equally and may occur at any
age. However, the incidence peaks in the third and sev-
enth decade of life.1,4 Although the cause remains un-
known, the disease results from progressive degeneration
of the plexus myentericus, resulting in a lack of inhibitory
neurons needed for coordination of lower esophageal
sphincter relaxation and peristaltic contractions of the
esophagus.4 While investigators suggest genetic, autoim-
mune, or infectious origin of the neural damage, the exact
cause remains to be determined.4,5
Clinical symptoms including dysphagia, chest pain, and
regurgitation are not specific to achalasia, which may
result in a 2-year to 3-year delay in diagnosis from the
beginning of symptoms.4 Severity of the disease has also
not been found to be linked to symptoms. Further diag-
nostic tests, including radiographic and manometric find-
ings are used to confirm the clinical diagnosis.6 Esopha-
geal manometry remains the primary diagnostic tool for
achalasia. An abnormal pressure measurement pattern is
found in patients with achalasia.6 Left untreated, most
patients will eventually develop a dilated “mega-esopha-
gus” with severe bolus transit impairment. Therefore, the
goal in the management of achalasia is early diagnosis and
treatment before reaching this end-stage phase when dys-
phagia may not be amenable to treatment other than
esophagectomy.7–10
Curing achalasia and reinstating esophageal peristalsis im-
plies restoring the neurons of the myenteric plexi. Until such
treatment becomes available, all interventions currently aim
at facilitating bolus transit across the LES. Therapies include
pharmacotherapy, chemical paralysis through Botox (botu-
linum toxin A) injection, mechanical dilation, and surgical
myotomy. The order in which these therapies are recom-
mended or performed is the subject of debate.11–12 Pharma-
cotherapy provides short-lived results, incomplete relief, and
efficacy that decreases with time. Therefore, it is generally
not considered a good treatment option for long-term relief
of symptoms.11,12 Surgical myotomy produces the most du-
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SCIENTIFIC PAPERrable long-term results.7 Minimally invasive myotomies offer
increasingly less morbidity, postoperative pain, and facilitate
an expeditious return to daily activities.7,11 Prior to the lapa-
roscopic myotomy, operations for achalasia were done ei-
ther through laparotomy or thoracotomy. The higher risks
associated with open surgery dissuaded many from recom-
mending surgical intervention as first-line treatment, espe-
cially to the elderly with their associated comorbidities.3,13,14
In the relatively short time since the first laparoscopic myot-
omy, patients undergoing minimally invasive myotomy have
demonstrated excellent symptomatic outcomes with low
morbidity and mortality.7 This has resulted in an increased
preference of surgery as the initial treatment strategy.7–14
While an increasing number of older patients are being
referred for laparoscopic Heller myotomy as the first-line
treatment, few studies have followed the impact age has on
surgical treatment of achalasia.3,13,14 The goal of this investi-
gation was to review the outcomes of minimally invasive
myotomies for achalasia in the elderly at our institution.
MATERIALS AND METHODS
After institutional review board consent was obtained, the
medical records of 52 consecutive patients aged 65 years
or older undergoing minimally invasive Heller myotomy
for achalasia were retrospectively reviewed. The diagnosis
of achalasia was confirmed by Barium esophagogram,
demonstrating the classic appearance of achalasia (prox-
imal esophageal dilation with a distal “bird’s peak”), and
esophageal manometry. The most common present symp-
tom was dysphagia (90%). Mean duration of symptoms for
the entire patient cohort was 10.9 years (minimum 0.5
years - maximum 50 years). Prior therapies for the treat-
ment of achalasia were documented (pneumatic dilations,
Botox, prior myotomy), and the postoperative clinical
outcomes were analyzed. Demographic data were ob-
tained. Outcome variables included perioperative morbid-
ity and mortality, symptom improvement, and postopera-
tive interventions.
Operative Technique
The laparoscopic Heller myotomy is performed using a
5-port technique, as previously described.7 Direct visualiza-
tion is used to enter the abdominal cavity 3 inches above the
umbilicus. Four additional ports are placed. The gastrohe-
patic ligament is opened widely using Harmonic shears. The
dissection then is carried up and down the right and left
crura and into the mediastinum for adequate mobilization of
the esophagus into the peritoneal cavity. Care is taken to
identify and preserve both the anterior and posterior vagus
nerves throughout the procedure. The short gastric vessels
are divided, freeing the fundus, and the gastroesophageal fat
pad is removed.
Hook cautery on a low wattage is used to divide the
longitudinal and then circular fibers of the esophagus,
completing a myotomy approximately 10cm up the
esophagus and 4cm down onto the anterior gastric wall.
To confirm an adequate myotomy, intraoperative endos-
copy is undertaken. An adequate myotomy is confirmed
when the endoscope passes easily into the stomach, the
gastroesophageal junction opens easily with endoscopic
air insufflation, and transillumination of the myotomized
segment confirms muscle division well above and below
the Z-line. A partial fundoplication was performed in the
majority of the patients.
Statistical Analysis
Data were maintained on an Excel spreadsheet (Microsoft,
Redmond, WA, USA). Statistical analysis was performed us-
ing SPSS software (Version 10; SPSS, Inc, Chicago, IL) and
included x
2 and Student t tests. Data are presented as means
and percentages for categorical data, means, and standard
deviations for continuous data. P0.05 was used to deter-
mine statistical significance.
RESULTS
Fifty-one patients, 29 women and 22 men with a mean age of
73.14 years (range 65 to 89) underwent laparoscopic Heller
myotomy at our institution. Twenty-eight patients (55%) had
undergone prior therapy (P0.075). Eight patients (29%)
received prior pneumatic dilation, 7 (25%) received prior
Botox, and 13 (46%) had both, with a mean period of time
between this strategy and the laparoscopic myotomy aver-
aging 12 months (range, 18 to 36). Two (7%) patients
had undergone previous myotomies more than 40 years
earlier with no improvement, and both patients had
been treated with multiple pneumatic dilations and
Botox injections (Table 1).
All operations were begun laparoscopically with one con-
version to open myotomy. The decision for conversion was
independent of the myotomy. In addition to an esophageal
myotomy, this patient was having a malpositioned Nissen
fundoplication taken down. The surgeon’s choice to convert
to open was based on the discovery of dense scar tissue that
prevented the release of the posterior portion of the wrap
from the esophagus. The median hospital stay was 3 days
(range, 1 to 26). Complications occurred in 2 (3.8%) patients;
1 patient had an intraoperative gastric perforation, which
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and 1 patient with postoperative atelectasis that required
discharge on supplemental oxygen. There was no perioper-
ative mortality.
Forty-eight patients (92.3%) had a partial fundoplication pro-
cedure. Thirteen (27%) received a Dor fundoplication, while
35 (73%) received Toupet fundoplication. The judgment not
to complete a fundoplication was based on the finding of
dense scarring from a previous fundoplication or compli-
cated anatomy. There was no difference in surgical outcome
or patient satisfaction in those patients who had a Dor or
Toupet fundoplication (Table 2).
Of the 42 patients with documented follow-up (mean time
42 months, range 24 to 53), all claimed overall symptom
improvement, although a minority had identifiable foods
that they restricted. The most common limitations in-
volved solid foods; meat and hot dogs were specifically
noted, which caused significant “sticking.” Despite these
notations, each patient claimed overall symptom improve-
ment. Eleven patients (22%) required additional therapy.
Five patients (46%) underwent additional pneumatic dila-
tions, 4 (36%) received pneumatic dilation and Botox
injections, one (9%) patient received Botox for recurrent
dysphagia and at a mean of 30 months (range, 6 to 53)
following the surgery. One patient (9%) underwent fur-
ther surgical intervention, receiving an esophagectomy 4
years later. This patient had an extremely complicated
history of achalasia since adolescence with severe pro-
gression of his symptoms. Of those 11 patients, 8 (73%)
had undergone therapy before the laparoscopic fundopli-
cation as well (P0.001) (Table 3).
DISCUSSION
Achalasia is a chronic disorder of the esophagus that
significantly impacts the quality of life of the patients.
Because the cause remains elusive, no specific therapy is
available for managing the underlying disease process.
Several available therapies have been developed to alle-
viate the symptoms of the disease. However, none of the
treatment options re-establish normal muscle activity of
the esophageal body and lower esophageal sphincter
(LES). Instead, all relieve the functional obstruction
caused by the failure of LES to relax upon deglutition.
Most treatment options are tailored to the patient’s overall
health status and underlying comorbidities.
Occurring in 1 of 100 000 people, achalasia has a bimodal
distribution, with a smaller peak in persons between 25
years and 40 years of age, and a larger peak occurring in
the seventh decade. Significant differences in the clinical
presentation between these 2 populations have been re-
ported.1,3–5,7,13,14 Older patients have been shown to ex-
perience significantly less frequent dysphagia, regurgita-
tion, and choking episodes premyotomy.14–17 Younger
patients have more severe symptoms, or less tolerance of
their symptoms, regardless of duration.15,17 Older patients
tend to present with more complaints of heartburn than
younger patients do.16
Table 1.
Demographic and Clinical of the Study Population
Age (yrs) 73.14 (65 to 89)
Sex (F/M) 29/22
Duration of Symptoms (yrs) 10 (5 to 50)
Preoperative LESP, mm Hg 32 (7 to 28)
Prior Therapy (Y/N) 28/23
Pneumatic dilation 8 (29%)
Botox® Injection 7 (25%)
Both 13 (46%)
Previous myotomy 2 (7%)
Time Between Procedures 12 (18 to 36)
Table 2.
Perioperative Outcomes
Fundoplication 48 (92.3%)
Dor 13 (27%)
Toupet 35 (73%)
Conversion to Open 1 (1.9%)
Complications
Intraoperative gastric perforation 1 (1.9%)
Atelectasis 1 (1.9%)
Length of Stay (d) 3 (1 to 26)
Table 3.
Postoperative Outcomes
Recurrent Symptoms 11 (22%)
Time of Dysphagia Recurrence (months) 30 (6 to 53)
Required Additional Therapy
Pneumatic Dilations 5 (50%)
Botox® Injections 1(10%)
Pneumatic Dilations  Botox® 4 (40%)
Esophagectomy 1 (1.9%)
Follow-up (months) 42 (24 to 53)
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unteers, which suggested that elderly subjects have a re-
duced sensitivity to esophageal balloon distention compared
with younger subjects. Moreover, acid sensitivity of the in-
flamed and uninflamed esophageal mucosa has been shown
to be largely dependent on the patient’s age.16 Because aging
notably decreases the frequency of episodic chest pain,
some patients will even lose this symptom over a period of
several years.17 Rakita et al3 examined a cohort of 262 pa-
tients (142 men and 120 women), with an average age of 49
years, who had undergone laparoscopic Heller myotomy.
Results supported the previous findings that older patients
were more likely to have a longer duration and less severe
symptoms before myotomy consistent with a more indolent
course of disease. Fortunately, postmyotomy results indi-
cated that neither age nor duration of symptoms influenced
long-term patient results3 and we could confirm that in our
population (Table 4). Whether distinct variants of achalasia
exist in the 2 age distributions or whether these differences
merely represent a spectrum of the same disease remains to
be elucidated.
The increased proficiency of surgeons in minimally invasive
techniques over the past 15 years has resulted in the laparo-
scopic modified Heller myotomy becoming the gold-stan-
dard treatment for achalasia in younger individuals (50
years old).7–10 However, some individuals suggest that older
patients should have a different approach to treatment, and
surgery should not be offered as the first line of therapy.
Several series favor botulinum toxin injections or pneumatic
balloon dilation (PD), but none have concluded a definitive
treatment approach.18–23 Most suggest that specific treat-
ments work better under certain circumstances such as the
early stages of the disease.19,21 However, these nonsurgical
options usually have to be repeated to achieve long-term
effects. As revealed in our study, most of our patients had
undergone nonsurgical treatment without satisfactory long-
term results before being referred for surgery.
Pneumatic dilation is recommended by many, because it is
associated with an initial success rate of 70%. However,
approximately 40% of patients experience symptom recur-
rence with extended follow-up in some series.18–20 Csendes
and colleagues20 found better long-term success in surgical
patients compared with those treated by balloon dilatation
alone. Farhoomand18 found a 37% recurrence of symptoms
within 3 months in patients treated initially with a 3.0-cm
balloon. Moreover Karamanolis et al19 found that even with
a clinical remission for more than 15 years after the initial
pneumatic dilation in 51.4% of their patients, the long-term
success rate dropped progressively with time, the need for
additional esophageal balloon dilation increased, as well as
the risk of perforation related to each procedure, and the
symptoms were less likely to abate. Our experience indicates
that pneumatic dilations offer relief; however, they often
require repeat dilations, each with decreasing efficacy.
Botox is usually reserved for physiologically compro-
mised individuals who cannot undergo PD or minimally
invasive myotomy (MIM). Vaezi et al,21 in a randomized
trial comparing Botox and PD, found that pneumatic di-
latation resulted in a significantly (P0.02) higher cumu-
lative remission rate. At 12 months, 14/20 (70%) pneu-
matic dilatation and 7/22 (32%) Botox-treated patients
were in symptomatic remission (P0.017). PD resulted in
significant (P0.001) reduction in symptom scores, lower
esophageal sphincter pressure measurements, esophageal
barium column heights, and esophageal diameters. Botox
produced a significant reduction in symptom scores
(P0.001), but no reduction in objective parameters. Fail-
ure rates were similar initially, but failure over time was
significantly (P0.01) higher after Botox (50%) than after
pneumatic dilatation (7%). Zaninotto et al22 published the
results of a randomized trial comparing 2 Botox injections
1 month apart (100 units each) with laparoscopic Heller
myotomy and fundoplication. There were 40 patients in
each group, no mortality in either group, and only 1 minor
complication in the surgery group. At 2-year follow-up,
nearly 66% of the Botox group was again symptomatic
compared with only 13.5% of the surgery group. An initial
resistance to Botox, caused by antibody formation, is
present in up to 26% of patients and likely contributes to
the method’s high primary failure rate. Moreover, in pa-
tients undergoing Botox injection, intramural fibrosis has
been reported that could interfere with subsequent surgi-
cal treatment. Neubrand23 reported a 70% success rate
Table 4.
Patients That Require Additional Therapy
No
Additional
Therapy
Additional
Therapy
P Value
Patients (n) 40 11 0.001
Age (yrs) 72 72 (68 to 79) 0.061
Sex (F/M) 24/17 5/5 0.444
Duration of Symptoms 10 11 (0.5 to 40) 0.879
Preoperative LESP,
mm Hg
31.4 (-) 36.3 (7 to 82) .004
Prior Therapy 20 8 0.001
Postoperative
Complications
1 1 0.512
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for 6 months to 9 months and only half of them benefit for
more than 1 year. He also found that younger patients
(55 years) usually have a higher LES pressure than older
patients, and they did not seem to benefit from botulinum
toxin injection.
Few publications of outcomes of MIM specifically in the
older population have been published. Kilic et al13 per-
formed MIM on 57 patients 70 years of age or older. This
group represented 25% of all achalasia patients on their
service. Symptom improvement was achieved in the vast
majority as assessed by dysphagia score (96.5%) as was
freedom from further surgical intervention (93.0%) at a mean
follow-up of approximately 2 years. The complication rate of
19.3% was managed without significant morbidity and non-
perioperative mortality. The authors state that one of the best
advantages of using MIM for older achalasia patients is the
avoidance of repeated procedures, because only 7% of their
patient’s required further intervention. Similar findings were
reported by Kala et al24 in the 8-year follow-up of 115
patients, with a senior subgroup of 26 (average 69.7). Post-
operative decrease of LES tone showed good motility results
of Heller myotomy, and 24-hour pH-metry revealed good
antireflux effects of Toupet fundoplication. In our study, all
the patients with a completed follow-up of 32 months
claimed overall symptom improvement, and only 11 patients
required further interventions.
The influence of prior nonsurgical therapy in the laparo-
scopic Heller myotomy outcome is still controversial. In an
analysis of 200 patients undergoing myotomy, predictors of
failure were prior therapy, duration of the symptoms, and
sigmoid esophagus.25 In our study, prior therapy and preop-
erative LESP, mm Hg had statistical significance between
patients who required additional therapy and those who did
not (P0.01 and P0.004, respectively). Smith et al12 in their
study of 209 patients undergoing Heller myotomy for acha-
lasia found that intraoperative complications were more
common in patients with previous therapies and postoper-
ative complications like primarily severe dysphagia or pul-
monary complications were more common after endoscopic
treatment (10.4% versus 5.4%), also myotomy failure was
higher in these patients (19.5% versus 10.1%). On the other
hand, Ferulano and colleagues2 assert that age and previous
treatment do not influence the outcome. They did not find
evidence that repeated dilations render surgery more diffi-
cult, even if mucosal tears had occurred in their patients who
had undergone previous treatments. While prior therapy
may make the actual surgery more demanding, our experi-
ence indicates that the long-term results remain unaffected.
Eleven of our 51 patients had additional therapy after surgi-
cal treatment. Eight of those 11 (73%) had also received
preoperative therapy. Twenty-three patients underwent a
laparoscopic Heller myotomy as the first-line treatment with
only 3 (13%) requiring further therapy. Our data suggest that
although preoperative therapy does not negatively affect the
outcome of the Heller myotomy, it makes a patient more
susceptible to additional therapy postoperatively. Schuchert25
concluded in his 200-patient study that prior endoscopic
therapy was associated with a higher risk of failure after
myotomy as well as reoperation rate. Surgery as a first-line
treatment is therefore advantageous in that it may prevent
additional procedures, which is also potentially advanta-
geous to the elderly population. In addition, patients receiv-
ing pneumatic dilations often seek surgery eventually. In the
event of a failed myotomy, re-do myotomy is generally
considered a formidable task, because of the adhesions and
dense fibrosis that destroy the planes within the LES.7 How-
ever, with the continually progressing techniques and im-
provements in advanced laparoscopy, re-do myotomy has
also been shown to be safe and effective.25
The majority of our patients had a partial fundoplication in
addition to the myotomy. Other authors have demonstrated
in randomized trials that the addition of a partial fundopli-
cation decreased the incidence of postoperative gastro-
esophageal reflux from 46.6% with Heller alone to 9.1% with
Heller/Dor, with no significant change in dysphagia.26,27
Twenty-seven percent of our patients undergoing fundopli-
cation received a Dor fundoplication, while 73% received a
Toupet fundoplication. Our study showed favorable results
with the addition of fundoplication, regardless of the tech-
nique. Follow-up records report overall improvement in de-
glutition symptoms, with a handful of patients citing inci-
dences of dysphagia with select foods. No patient
complained of reflux at the time of follow-up, suggesting
that both Dor and Toupet are effective fundoplication
procedures. Ultimately, surgeon experience and prefer-
ences dictated procedure choice.
All patients reported an improvement in symptoms at
follow-up. A minority of patients noted specific foods
or incidences that caused dysphagia. However, relative
to initial symptoms, all patients claimed improvement.
Our data are consistent with that of other studies that
also indicate an overwhelming degree of symptom im-
provement.3,9,11,13,25 Heller myotomy provides high pa-
tient satisfaction and significant symptom improve-
ment, both of which play critical roles in determining a
treatment.
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Our data suggest that laparoscopic Heller myotomy
should be offered as a first-line treatment for elderly pa-
tients with achalasia who are fit for surgery. The proce-
dure has proven to be safe and effective in this popula-
tion. Prior endoscopic therapy does not appear to
adversely effect postoperative symptom improvement,
but may help predict those patients who might require
further therapy postoperatively.
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